FDA
-
-
-
-
-
-
-
Rezolute presents additional Phase 3 sunRIZE data at pediatric meeting
-
-
-
-
-
-
-
Rezolute meets with FDA on failed congenital hyperinsulinism study
-
-
-
-
-
-
-
Rezolute phase 3 trial for congenital hyperinsulinism fails to meet endpoints
-
-
-
-
-
-
-
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
-
-
-
-
-
-
-
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
BTIG Reiterates Neutral Rating on Rezolute (RZLT)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)
-
328,457 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

